U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H13N
Molecular Weight 159.2276
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PARGYLINE

SMILES

CN(CC#C)CC1=CC=CC=C1

InChI

InChIKey=DPWPWRLQFGFJFI-UHFFFAOYSA-N
InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3

HIDE SMILES / InChI

Description

Pargyline is an irreversible selective monoamine oxidase (MAO)-B inhibitor, which possesses higher selectivity to this isoform in comparison with MAO-A. It was approved under brand name eutonyl for the treatment hypertension, but then this drug was discontinued.

Originator

Approval Year

1963
72
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Eutonyl

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
75 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/490428/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PARGYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
272 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/490428/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PARGYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/490428/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PARGYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2E1
1060

CYP2B1
14

CYP1A1
132
CYP2B1
12

CYP2E1
729
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
272
 yes
CYP2B1
41
 yes
CYP2E1
1146
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2B1
12
 yes
CYP2E1
729
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B3-049611
http://www.3bsc.com/index/pro_info.php?id=87188
AA Blocks
AA0030KE
http://www.aablocks.com/goods/Goods/detail?id=AA0030KE
Aaron Chemicals
AR0031C6
http://www.aaronchem.com/306-07-0
abcr GmbH
AB125516
http://www.abcr.de/shop/en/AB125516
AbMole Bioscience
M5860
http://www.abmole.com/products/pargyline-hcl.html
Acadechem
ACDS-034173
http://www.acadechemical.com/product/108872
Accela ChemBio Inc
SY005867
http://www.accelachem.com/cn/search.html?keyword=SY005867&attname=GoodsCode
Achemo Scientific Limited
AC-13195
http://www.achemo.com/product_view.asp?ID=3085
Achemtek
0104-045712
http://www.achemtek.com/306-07-0
Acorn PharmaTech
ACN-038017
http://www.acornpharmatech.com/
AEchem Scientific Corp., USA
AE026498
http://www.aechemsc.com/info_products/AE026498.php
AHH Chemical co.,ltd
MT-18749
http://www.ahhchemical.com/product/MT-18749.html
AK Scientific, Inc. (AKSCI)
V1637
http://www.aksci.com/item_detail.php?cat=V1637
Alfa Chemistry
AP306070
https://reagents.alfa-chemistry.com/product/pargyline-hydrochloride-cas-306-07-0-9607.html
Ambeed
A200574
https://www.ambeed.com/products/306-07-0.html
Ark Pharm
AK139345
http://www.arkpharminc.com/products/306-07-0.html
Aurum Pharmatech LLC
Z-3950
http://www.Aurumpharmatech.com/Product/ProductDetails/Z_3950
BioChemPartner
BCP21320
http://www.biochempartner.com/306-07-0-BCP21320
BLD Pharm
BD146773
http://www.bldpharm.com/products/306-07-0.html
BOC Sciences
306-07-0
https://www.bocsci.com/pargyline-hydrochloride-cas-306-07-0-item-65649.html
Boerchem
BC214776
http://www.boerchem.com/?product_36301.html
Chem Scene
CS-4338
http://www.chemscene.com/306-07-0.html
ChemMol
30106833
http://www.chemmol.com/chemmol/30106833.html
ChemMol
44004962
http://www.chemmol.com/chemmol/44004962.html
ChemMol
97800520
http://www.chemmol.com/chemmol/97800520.html
ChemMol
99068671
http://www.chemmol.com/chemmol/99068671.html
Chemspace
CSSB00000104088
https://chem-space.com/CSSB00000104088
Combi-Blocks
ST-3774
http://www.combi-blocks.com/cgi-bin/find.cgi?ST-3774
CSNpharm
CSN11654
https://www.csnpharm.com/products/n-methyl-n-propargylbenzylamine-hydrochloride.html
DC Chemicals
DC10604
http://www.dcchemicals.com/product_show-PARGYLINE-HYDROCHLORIDE.html
Debye Scientific
DB-047811
http://www.debyesci.com/cas_306-07-0.html
eNovation Chemicals
D571728
http://www.enovationchem.com/productDetails.asp?productID=D571728
eNovation Chemicals
K95484
https://www.enovationchem.com/ProductDetails.asp?ProductID=K95484
Finetech
FT-0631924
http://www.finetechnology-ind.com/prod/detail/pub/306-07-0.html
Glentham Life Sciences
GP7491
http://www.glentham.com/products/product/GP7491/
iChemical
EBD53833
http://www.ichemical.com/chemicals/cas-306-07-0
Lab Network
LN01289095
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01289095
Lan Pharmatech
LAN-B00758
http://www.lanpharmatech.com/product-9?_keywords=LAN-B00758
LGC Standards
LGCFOR1912.00
https://www.lgcstandards.com/US/en/p/LGCFOR1912.00
LGC Standards
MM1912.00
https://www.lgcstandards.com/US/en/p/MM1912.00
mcule
MCULE-9689491047
https://mcule.com/MCULE-9689491047/
MedChem Express
HY-A0091
https://www.medchemexpress.com/Pargyline-hydrochloride.html
MolPort
MolPort-003-666-254
https://www.molport.com/shop/molecule-link/MolPort-003-666-254
MuseChem
I003079
https://www.musechem.com/product/I003079.html
Oakwood
336074
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=150450&ExtHyperLink=1
Selleck Chemicals
S3690
http://www.selleckchem.com/products/pargyline-hydrochloride.html
Sigma-Aldrich
1499006_USP
http://www.sigmaaldrich.com/catalog/product/usp/1499006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
191736_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/191736?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
P8013_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/p8013?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S018516
http://www.sinfoobiotech.com/product/1021914
Smolecule
S538643
http://www.smolecule.com/products/s538643
THE BioTek
bt-278862
https://www.thebiotek.com/product/inhibitors/bt-278862
Vesino Industrial Co Ltd
VA11492
http://www.vsnchem.com/goto/product/22815/
Yuhao Chemical
JZ0623
http://www.chemyuhao.com/306-07-0.html
PubMed

PubMed

TitleDatePubMed
Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
2015-03-25
Acute effects of resveratrol to enhance cocaine-induced dopamine neurotransmission in the striatum.
2013-05-10
Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy.
2010-11-01
Alterations in hippocampal serotonergic and INSR function in streptozotocin induced diabetic rats exposed to stress: neuroprotective role of pyridoxine and Aegle marmelose.
2010-09-25
IRAK-M regulates chromatin remodeling in lung macrophages during experimental sepsis.
2010-06-16
Clinical review: immunomodulatory effects of dopamine in general inflammation.
2004-12
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
2004-05-25
GABAergic and dopaminergic systems may be involved in seizures induced by pyrimethamine in mice.
1994-10
The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine.
1994-07-11
The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice.
1993-10-15
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
1987-09
Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.
1987
[Effects of pentoxifylline on 5-hydroxytryptamine in the mouse brain].
1985-11
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats.
1985-10
Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia.
1984-09
Pargyline-induced mania in primary affective disorder: case report.
1983-01
The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
1982-11-15
Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients.
1982-05
Determination of the role of serotonergic and cholinergic systems in apomorphine--induced aggressiveness in rats.
1979-03-01
Testosterone-attenuated stereotype and hyperactivity induced by beta-phenylethylamine in pargyline-pretreated rats.
1978-08
Role of the sympathetic nervous system in daunomycin-induced arrhythmia in the monkey.
1970-07
Patents

Patents

07524846
4
07601744
2
JP2009062371A
2

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The two molecular forms of monoamine oxidase (MAO), MAO-A and MAO-B, were determined quantitatively in discrete regions of the human brain at autopsy, and in cerebral microvessels, choroid plexus and liver samples from the same subjects. MAO was assessed by specific[3H] pargyline binding, which is stoichiometric and irreversible, and by measuring the rate of oxidation of several MAO substrates. Basal ganglia structures (caudate, putamen, globus pallidus and substantia nigra) and hippocampus had about twice the levels of MAO that were present in the cerebral cortex and cerebellum. Cerebral microvessels, which constitute the blood-brain barrier, had minimal MAO, while the choroid plexus, which constitutes the blood-cerebrospinal fluid barrier, and the liver had higher MAO levels than any brain region. The vast majority of MAO (80-95%) in these tissues was of the B type, except in microvessels, where total MAO activity was low. Specific [3H]pargyline binding correlated well with the oxidation rates for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and benzylamine in all tissues. Both specific [3H]pargyline binding and the rate of oxidation of MAO substrates increased with age.
Unknown
Name Type Language
PARGYLINE [MI]
Preferred Name English
PARGYLINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
BENZENEMETHANAMINE, N-METHYL-N-2-PROPYNYL-
Systematic Name English
pargyline [INN]
Common Name English
Pargyline [WHO-DD]
Common Name English
PARGYLINE [VANDF]
Common Name English
N-METHYL-N-2-PROPYNYLBENZYLAMINE
Systematic Name English
Classification Tree Code System Code
WHO-ATC C02LL01
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
NCI_THESAURUS C270
Created by admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
WHO-VATC QC02LL01
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
NCI_THESAURUS C667
Created by admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
WHO-VATC QC02KC01
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
WHO-ATC C02KC01
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
Code System Code Type Description
DRUG BANK
DB01626
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
IUPHAR
7262
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
DRUG CENTRAL
2065
Created by admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
PRIMARY
EPA CompTox
DTXSID3023423
Created by admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
PRIMARY
CAS
555-57-7
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
SMS_ID
100000082797
Created by admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
PRIMARY
FDA UNII
9MV14S8G3E
Created by admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
PRIMARY
INN
1350
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
MESH
D010293
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
ECHA (EC/EINECS)
209-101-6
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
MERCK INDEX
m8412
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY Merck Index
PUBCHEM
4688
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
RXCUI
7930
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY RxNorm
NCI_THESAURUS
C66322
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
EVMPD
SUB09626MIG
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
WIKIPEDIA
PARGYLINE
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
ChEMBL
CHEMBL673
Created by admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of PARGYLINE
SALT/SOLVATE (PARENT)
Structure of PARGYLINE HYDROCHLORIDE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966